Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 51Specimen Handling 42enzalutamide 36Androgen Antagonists 35Radiosurgery 33Radiotherapy 31darolutamide 27Prednisone 26Abiraterone Acetate 25Leuprolide 22Docetaxel 22apalutamide 21Pluvicto 20abiraterone 19Standard of Care 18Triptorelin Pamoate 17Radiation 17Biopsy 16relugolix 15acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Goserelin 14gallium 68 PSMA-11 13Blood Specimen Collection 13X-Rays 11Surveys and Questionnaires 11pembrolizumab 10luprolide acetate gel depot 10Carboplatin 10Methods 9Interviews as Topic 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Prostatic Neoplasms × Prodrugs × Clear all
NCT07332000 2026-03-20

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Candel Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡